Literature DB >> 11570904

Malignant melanoma.

A Slominski1, J Wortsman, A J Carlson, L Y Matsuoka, C M Balch, M C Mihm.   

Abstract

CONTEXT: The rapidly developing fields of melanoma research are revolutionizing the current concepts on melanoma etiology and pathogenesis and are introducing newer diagnostic techniques and potential therapeutic approaches.
OBJECTIVES: To present the most current concepts on the etiology and pathogenesis of melanoma and to introduce the recent diagnostic techniques and the potential therapeutic approaches.
METHODS: Data sources were reports on melanoma published in the English language literature and observations made using specimens available at Harvard University, Johns Hopkins Medical Center, Albany Medical College, Loyola University Medical Center, and University of Tennessee Health Science Center.
RESULTS: Studies on melanoma containing chromosomal or genetic evaluation were selected for further analysis. Current clinical and pathologic categories with the reported genetic abnormalities were related to the latest information on pigment biology. The data extracted were used to develop a conceptual framework on the pathogenesis of melanoma; the generated model was then evaluated and used to suggest potential therapeutic approaches.
CONCLUSIONS: (1) Melanoma is not genetically homogeneous, and the existing differences between the pathologic categories, particularly in areas such as type of growth phase (radial vs vertical growth), total vertical dimension, ulceration of primary tumor, and metastatic process, have profound prognostic and therapeutic implications. (2) Chromosomal aberrations and gene mutations are found in sporadic and familial melanomas; among the most important are those affecting the 9p21, which contains the p16 locus, a site known to be critical for normal progression of the cell cycle. Aberrant p16 expression is associated with more aggressive behavior. (3) Melanoma cells possess a remarkable repertoire of biosynthetic capacities represented by the production of hormones, growth factors, and their receptors that may sustain and accelerate tumor development and progression. For example, expression of the tumoral products alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone is regulated in vitro by ultraviolet light, a known carcinogen. (4) Melanomas differ from other tumors in their intrinsic capability to express melanogenic enzymes with the corresponding structural proteins to actually synthesize melanin. Melanogenesis-related proteins are rapidly entering the clinical arena, being used not only as diagnostic markers, but also as potential targets for melanoma therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570904     DOI: 10.5858/2001-125-1295-MM

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  30 in total

1.  Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity.

Authors:  Michal A Zmijewski; Wei Li; Jianjun Chen; Tae-Kang Kim; Jordan K Zjawiony; Trevor W Sweatman; Duane D Miller; Andrzej T Slominski
Journal:  Steroids       Date:  2010-11-09       Impact factor: 2.668

2.  Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.

Authors:  Pawel Mroz; Ying-Ying Huang; Angelika Szokalska; Timur Zhiyentayev; Sahar Janjua; Artemissia-Phoebe Nifli; Margaret E Sherwood; Christian Ruzié; K Eszter Borbas; Dazhong Fan; Michael Krayer; Thiagarajan Balasubramanian; Eunkyung Yang; Hooi Ling Kee; Christine Kirmaier; James R Diers; David F Bocian; Dewey Holten; Jonathan S Lindsey; Michael R Hamblin
Journal:  FASEB J       Date:  2010-04-12       Impact factor: 5.191

3.  Interfering growth of malignant melanoma with Ang2-siRNA.

Authors:  Biao Wang; Zhaoliang Liu; Mingfeng Zhang; Xiuying San; Yanding Zhang; Weiqiang Zhang; Meishui Wang
Journal:  Mol Biol Rep       Date:  2012-11-16       Impact factor: 2.316

4.  The UK Government two-week rule and its impact on melanoma prognosis: an evidence-based study.

Authors:  M D Pacifico; R A Pearl; R Grover
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

Review 5.  Malignant melanoma and melanocortin 1 receptor.

Authors:  A A Rosenkranz; T A Slastnikova; M O Durymanov; A S Sobolev
Journal:  Biochemistry (Mosc)       Date:  2013-11       Impact factor: 2.487

6.  Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.

Authors:  Toshihiko Hoashi; Shinichi Sato; Yuji Yamaguchi; Thierry Passeron; Kunihiko Tamaki; Vincent J Hearing
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

7.  Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.

Authors:  Andrzej Slominski; Blazej Zbytek; Radomir Slominski
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

Review 8.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

9.  PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.

Authors:  Maja Grabacka; Wojciech Placha; Krystyna Urbanska; Piotr Laidler; Przemysław M Płonka; Krzysztof Reiss
Journal:  Pigment Cell Melanoma Res       Date:  2008-04-26       Impact factor: 4.693

10.  Current concepts of metastasis in melanoma.

Authors:  Blazej Zbytek; J Andrew Carlson; Jacqueline Granese; Jeffrey Ross; Martin C Mihm; Andrzej Slominski
Journal:  Expert Rev Dermatol       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.